The nephroprotective potential of trimetazidine in chronic inflammation and oxidative stress in renal disease

The available studies provide an apparent compilation of diverse and solid research evidence on the possible nephroprotective role of trimetazidine. However, large, randomized, placebo-controlled, preferably multicentre studies are necessary to confirm this hypothesis in non-dialyzed, chronic renal failure and haemodialyzed patients. The extent of the challenge would also be related to specific molecular parameters chosen to demonstrate nephroprotection in the case of trimetazidine.